5 Things You'll Want to Watch With AbbVie's Q3 Results
If 2017 ended right now, it would go down as AbbVie's (NYSE: ABBV) best ever. The biotech stock's price has risen a little more than the 50% gains AbbVie made during its first year as a stand-alone company in 2013. AbbVie has enjoyed good news for its current products and its pipeline.
But the year isn't over yet. AbbVie will provide an update on its third-quarter performance on Friday. Will those results allow the company to keep the momentum rolling? Here are five things to watch with AbbVie's third-quarter results.
Image source: Getty Images.
Source: Fool.com
Johnson & Johnson Aktie
Johnson & Johnson erfreut sich großer Beliebtheit, mit einer hohen Zahl an Buy- und niedriger Zahl an Sell-Einschätzungen.
Das Kursziel von 194 € für Johnson & Johnson impliziert eine deutliche Steigerung um über 20% gegenüber 148.28 €.